Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Fox

Showing results (41-50 of 256) with videos related to

Pageof 26
Sort By:
Journal of Neurovirology|March 31, 2016
Erratum to: Reassessing the risk of natalizumab-associated PMLJoseph R Berger, Robert J Fox
The Lancet. Neurology|December 25, 2003
Multiple sclerosis: disease markers accelerate progressRobert J Fox, Richard A Rudick
Neurology|May 15, 2009
Seeing injectable MS therapies differently: they are more similar than differentRobert J Fox, Douglas L Arnold
Neurology|April 23, 2025
A Newly Validated Gold Standard for Measuring Multiple Sclerosis Disability WorseningRobert J Fox, Richard A Rudick
Seminars in Neurology|May 28, 2013
BG-12 in multiple sclerosisJ Theodore Phillips, Robert J Fox
Continuum (Minneapolis, Minn.)|June 5, 2016
Progressive Multiple SclerosisMary Alissa Willis, Robert J Fox
Neurology|May 26, 2021
A New Way to Identify Promising Therapies for Progressive Multiple SclerosisRobert J Fox, Richard J Kryscio
The Lancet. Neurology|September 20, 2025
Translating MRI advances into multiple sclerosis diagnosis: bridging science and clinical practiceRobert J Fox, Stephen E Jones
Nature Clinical Practice. Neurology|August 26, 2006
Should patients with relapsing multiple sclerosis be given a higher dose and frequency of interferon-beta1a?Robert J Fox, Richard A Rudick
Trends in Immunology|November 9, 2004
New directions in MS therapeutics: vehicles of hopeRobert J Fox, Richard M Ransohoff
Pageof 26

Showing results (41-50 of 256) with videos related to

Sort By:
Pageof 26
Journal of Neurovirology|March 31, 2016
Erratum to: Reassessing the risk of natalizumab-associated PMLJoseph R Berger, Robert J Fox
The Lancet. Neurology|December 25, 2003
Multiple sclerosis: disease markers accelerate progressRobert J Fox, Richard A Rudick
Neurology|May 15, 2009
Seeing injectable MS therapies differently: they are more similar than differentRobert J Fox, Douglas L Arnold
Neurology|April 23, 2025
A Newly Validated Gold Standard for Measuring Multiple Sclerosis Disability WorseningRobert J Fox, Richard A Rudick
Seminars in Neurology|May 28, 2013
BG-12 in multiple sclerosisJ Theodore Phillips, Robert J Fox
Continuum (Minneapolis, Minn.)|June 5, 2016
Progressive Multiple SclerosisMary Alissa Willis, Robert J Fox
Neurology|May 26, 2021
A New Way to Identify Promising Therapies for Progressive Multiple SclerosisRobert J Fox, Richard J Kryscio
The Lancet. Neurology|September 20, 2025
Translating MRI advances into multiple sclerosis diagnosis: bridging science and clinical practiceRobert J Fox, Stephen E Jones
Nature Clinical Practice. Neurology|August 26, 2006
Should patients with relapsing multiple sclerosis be given a higher dose and frequency of interferon-beta1a?Robert J Fox, Richard A Rudick
Trends in Immunology|November 9, 2004
New directions in MS therapeutics: vehicles of hopeRobert J Fox, Richard M Ransohoff
Pageof 26